Patent application number | Description | Published |
20090004213 | COMBINATION THERAPY USING ACTIVE IMMUNOTHERAPY - The present invention relates to methods of treating cancer in a mammal comprising administering to the mammal a combination therapy comprising a vaccine and a multi-kinase inhibitor, wherein the vaccine comprises an isolated tumor associated peptide having the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or class-II. Preferably the multi-kinase inhibitor is sunitinib malate and/or sorafenib tosylate or a pharmaceutically acceptable salt thereof. | 01-01-2009 |
20090123489 | NOVEL IMMUNOTHERAPY AGAINST NEURONAL AND BRAIN TUMORS - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 11 novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 05-14-2009 |
20090136528 | NOVEL IMMUNOGENIC EPITOPE FOR IMMUNOTHERAPY - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses. | 05-28-2009 |
20090148400 | COMPOSITION OF TUMOUR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE - The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumour immune responses against colorectal cancer. | 06-11-2009 |
20090274714 | TUMOUR-ASSOCIATED PEPTIDES BINDING TO HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS I OR II MOLECULES AND RELATED ANTI-CANCER VACCINE - The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to two novel peptide sequences derived from HLA class II molecules of human tumour cell lines, which can be used in vaccine compositions for eliciting anti-tumour immune responses. | 11-05-2009 |
20100158931 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 06-24-2010 |
20110002963 | COMPOSITION OF TUMOR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE FOR THE TREATMENT OF GLIOBLASTOMA (GBM) AND OTHER CANCERS - The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gliomas. | 01-06-2011 |
20110117117 | NOVEL IMMUNOGENIC EPITOPES FOR IMMUNOTHERAPY - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses. | 05-19-2011 |
20130004456 | COMPOSITION OF TUMOR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE FOR THE TREATMENT OF GLIOBLASTOMA (GBM) AND OTHER CANCERS - The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gliomas. | 01-03-2013 |
20140271692 | NOVEL IMMUNOGENIC EPITOPES FOR IMMUNOTHERAPY - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses. | 09-18-2014 |
20150023993 | COMBINATION THERAPY USING ACTIVE IMMUNOTHERAPY - The present invention relates to methods of treating cancer in a mammal comprising administering to the mammal a combination therapy comprising a vaccine and a multi-kinase inhibitor, wherein the vaccine comprises an isolated tumor associated peptide having the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I or class-II. Preferably the multi-kinase inhibitor is sunitinib malate and/or sorafenib tosylate or a pharmaceutically acceptable salt thereof. | 01-22-2015 |
Patent application number | Description | Published |
20080306902 | SYSTEM AND METHOD FOR TRACKING PRINT JOB STATUS - A system and method to track and display the status of an electronic document submitted through a web-portal to a multifunctional peripheral device. The multifunctional peripheral device receives an electronic document file upon which it is to perform a service and logs the receipt in a central status database. During the processing of the electronic document file, the multifunctional peripheral device continually updates the status information corresponding to that file in the central status database. Through a web-portal, a user selects from a list of recently submitted document files one file for which status information is desired. The multifunctional peripheral device then accesses the central status database, retrieves the file, and displays, via the web-portal, detailed document and status information corresponding to the selected document file. | 12-11-2008 |
20090158152 | SYSTEM AND METHOD FOR GENERATING CONTEXT SENSITIVE HELP FOR A GRAPHICAL USER INTERFACE - The subject application is directed to a system and method for generating context sensitive help for a graphical user interface. Display data corresponding to a plurality of indicia is first generated on an associated display, each indicia corresponding to a functionality of an associated information processing device. Selection data is then received corresponding to a selected indicia from those displayed. A touch down signal is then received corresponding to a tactile exertion of positive physical pressure. Duration data representing the duration of the exerted positive physical pressure is then received. A display of data associated with the functionality of the information processing device is subsequently triggered in accordance with the selected indicia corresponding to the received selection data and the received duration data. | 06-18-2009 |
20090204644 | SYSTEM AND METHOD FOR ON-DEMAND GENERATION OF A SELECTABLE INPUT FOR ENACTING A PREVIOUS DOCUMENT PROCESSING DEVICE CONTROL SEQUENCE - The subject application is directed to a system and method for on-demand generation of a selectable input for enacting a previous document processing device control sequence. User identification data is received, and a document processing session is opened. A sequence of instructions is then received, and data associated with the sequence is logged according to identification data. After the session opening, logged data is stored in associated memory. Data of a request to generate a selectable input corresponding to the logged data is then received, and testing is performed to determine whether data has been logged in a current session. Data logged during the session is associated with the selectable input, and stored data is retrieved and associated with the selectable input when no data has been logged during the current session. The sequence of selected instructions is then commenced upon the selection of the selectable input by the user. | 08-13-2009 |
20090300484 | SYSTEM AND METHOD FOR LOCAL MODIFICATION OF REMOTELY SUBMITTED DOCUMENT PROCESSING JOBS - The subject application is directed to rendering a remotely submitted document processing job using secondary job processing parameters specified at the rendering device. Electronic document data, associated identification data, and initial instruction data is received via a remote client interface. Location data of a selected rendering device is received via the remote interface, and the received job data is stored in a data storage associated with the device. The device's local interface receives login data, which is tested against the identification data. A display is selectively generated of the instruction and document data based on the testing output. Modified instruction data is received via the local interface relative to the initial instruction data. The costs for rendering the document data via the device are then calculated and displayed on the local interface. Following receipt of approval data via the local interface, a rendering operation is commenced on the document data. | 12-03-2009 |
Patent application number | Description | Published |
20090247725 | Methods for Preparing Oxydiphthalic Anhydrides, Oxydiphthalic Anhydrides Prepared Thereby, and Polyetherimides Derived Therefrom - a method for preparing an oxydiphthalic anhydride comprises contacting, under reactive and substantially anhydrous conditions in a reactor, at least one halophthalic anhydride containing more than 250 ppm chlorophthalide impurity with a carbonate of the formula M | 10-01-2009 |
20090247727 | Method of Purifying Dianhydrides, the Dianhydrides Formed Thereby, and Polyetherimides Formed Therefrom - A method for purifying an oxydiphthalic anhydride comprises diluting a first mixture comprising an oxydiphthalic anhydride, a solvent, a catalyst, and an inorganic salt with a solvent, to provide a second mixture having a solids content of 10 to 30 percent based on total weight of the second mixture; filtering and washing the solids of the second mixture at a temperature below the crystallization point temperature of the oxydiphthalic anhydride to provide a third mixture; hydrolyzing the third mixture by adding water and a water-soluble acid to form a fourth mixture; heating the fourth mixture; then cooling to provide a solid-liquid mixture, optionally decanting a portion of the liquid, rediluting the remaining solid-liquid mixture, then filtering to provide a solid component; washing the solid component with water to provide a fifth mixture of oxydiphthalic tetraacid and water; ring closing the oxydiphthalic tetraacid to provide oxydiphthalic anhydride, and filtering the oxydiphthalic anhydride. | 10-01-2009 |
Patent application number | Description | Published |
20110229504 | Novel immunotherapy against several tumors including gastrointestinal and gastric cancer - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 09-22-2011 |
20110229505 | Methods for the diagnosis and treatment of cancer based on AVL9 - The present invention relates to methods for the diagnosis and treatment of cancer in mammals, in particular gastric cancer, based on the new target AVL9. The present invention thus relates to diagnostic methods and related components to be used in such methods. Furthermore, the present invention relates to the treatment of cancer in mammals, in particular gastric cancer, based on AVL9 as a target. Specifically, the present invention relates to the immunotherapy of cancer using AVL9 tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides, and respective pharmaceutical compositions, in particular vaccine compositions. | 09-22-2011 |
20110229524 | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of Gastric Cancer and other cancers - The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gastric cancers (GC). | 09-22-2011 |
20120027684 | CANCER THERAPY BASED ON TUMOR ASSOCIATED ANTIGENS DERIVED FROM CYCLIN D1 - The present invention relates to cyclin D1-derived peptides for use in the improved treatment of cancer in a patient, particularly in the form of a combination therapy using a vaccine. Other aspects relate to the use of the peptides or a combination thereof as a diagnostic tool. | 02-02-2012 |
20120070461 | USE OF MYELOID CELL BIOMARKERS FOR THE DIAGNOSIS OF CANCER - The present invention relates to the use of myeloid cell biomarkers for the differential diagnosis, prognosis, and monitoring of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to monitoring the effect of a treatment against renal cell carcinoma (RCC) or colorectal cancer (CRC), and establishing a prognosis of the outcome of the treatment of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to panels of cellular biomarkers for use in the above methods, in particular multicolor panels for measuring said biomarkers. | 03-22-2012 |
20120128702 | NOVEL BIOMARKERS FOR A PREDICTION OF THE OUTCOME OF AN IMMUNOTHERAPY AGAINST CANCER - The present invention relates to methods for predicting the effect of an immunotherapy against cancer in a patient based on new biomarkers. The present invention furthermore relates to a prognosis regarding the outcome based on said biomarkers. The present invention furthermore relates to panels of biomarkers for use in the above methods. | 05-24-2012 |
20120141517 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 06-07-2012 |
20130045191 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 02-21-2013 |
20130177525 | CANCER THERAPY BASED ON TUMOR ASSOCIATED ANTIGENS DERIVED FROM CYCLIN D1 - The present invention relates to cyclin D1-derived peptides for use in the improved treatment of cancer in a patient, particularly in the form of a combination therapy using a vaccine. Other aspects relate to the use of the peptides or a combination thereof as a diagnostic tool. | 07-11-2013 |
20130309193 | COMPOSITION OF TUMOR-ASSOCIATED PEPTIDES AND RELATED ANTI-CANCER VACCINE FOR THE TREATMENT OF GLIOBLASTOMA (GBM) AND OTHER CANCERS - The present invention relates to immunotherapeutic peptides and their use in immunotherapy, in particular the immunotherapy of cancer. The present invention discloses tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the composition of the peptides of the present invention can be used in vaccine compositions for eliciting anti-tumor immune responses against gliomas. | 11-21-2013 |
20140234347 | METHODS OF USING BIOMARKERS FOR PREDICTING THE OUTCOME OF AN IMMUNOTHERAPY AGAINST CANCER - The present invention relates to methods for predicting the effect of an immunotherapy against cancer in a patient based on new biomarkers. The present invention furthermore relates to a prognosis regarding the outcome based on said biomarkers. The present invention furthermore relates to panels of biomarkers for use in the above methods. | 08-21-2014 |
Patent application number | Description | Published |
20130331510 | HIGH TEMPERATURE HYDROCARBON RESISTANT POLYURETHANE ARTICLES - Embodiments of the invention generally relate to polyurethanes having resistance to hydrocarbons and articles made therefrom. In one embodiment, a hydrocarbon resistant polycarbonate elastomer containing article is provided. The hydrocarbon resistant polycarbonate elastomer is prepared from a reaction mixture comprising (a) one or more difunctional polycarbonate polyols comprising repeating units from one or more alkane diols having 2 to 20 carbon atoms with a number average molecular weight between 500 and 3,000, and (b) one or more organic polyisocyanate components, wherein the article is selected from filter caps, conduits, containers, seals, mechanical belts, liners, coatings, rollers and machine parts. | 12-12-2013 |
20140088245 | HYDROPHOBIC POLYESTER POLYCARBONATE POLYOLS FOR USE IN POLYURETHANE APPLICATIONS - Disclosed are hydrophobic polyester-polycarbonate polyols which are the reaction product of (a) a polyester polyol and (b) one or more polycarbonate polyols. The polyester polyol (a) is the reaction product of: (i) one or more hydrophobic monomers, (ii) one or more organic acids, and (iii) one or more alcohols having an OH functionality of 2 or more. The polyester-polycarbonate polyols may be both amorphous and liquid at room temperature and have excellent hydrolytic stability. The hydrolytic and chemical performance of the polyester-polycarbonate polyols described herein is superior to that of commercially available hydrophobically modified polyester polyols and to that of commercially available polyester-polycarbonate polyols as described herein. | 03-27-2014 |
20140107288 | HYDROPHILIC POLYESTER POLYCARBONATE POLYOLS FOR HIGH TEMPERATURE DIESEL APPLICATIONS - Embodiments of the invention generally relate to polyols having resistance to hydrocarbons and articles made therefrom. More specifically, embodiments of the invention generally relate to hydrophilic polyester-polycarbonate polyols having resistance to hydrocarbons at high temperatures and articles made therefrom. The novel hydrophilic polyester-polycarbonate polyols described herein may be used in adhesive or elastomer applications requiring enhanced oil and/or diesel resistance. The disclosed polyols are liquid at room temperature, which facilitates processing into polyurethane products As described herein, an elastomer made from such hydrophilic polyester-polycarbonate polyols and methylene diphenyl diisocyanate (MDI) retained >90% of tensile strength after 500 hours ageing at 121 degrees Celsius. A comparative example made from a polyester polyol retained 50% of tensile strength under similar conditions. | 04-17-2014 |
20140352904 | ELASTOMERS FOR PAPER MILL EQUIPMENT - Embodiments of the invention provide for paper mill equipment that can better withstand the conditions of a paper Mill. Embodiments encompass paper mill equipment that incorporate a polyurethane layer having a hysteresis value of less than 70% and a permanent set of less than 30%. The polyurethane layer includes a polyurethane produced by curing a mixed composition. The mixed composition includes at least a urethane prepolymer (A) and at least a curing agent (B) having an active hydrogen group (H). The urethane prepolymer (A) has at least one terminal isocyanate group and is obtained by reacting at least a polyisocyanate compound (a) with at least a polycarbonate diol compound (b) having a number average molecular weight of at least 1500 g/mol. The curing agent (B) includes at least an amine compound. The elastomer compositions are also useful to coat the acid pickling roller in the steel industry. | 12-04-2014 |
20150018512 | SINGLE-POT PROCESS FOR THE PRODUCTION OF POLYESTER-CO-CARBONATE POLYOLS - Polyester-co-carbonate polyols and methods for producing the same are provided. The method comprises reacting one or more alcohols having an OH functionality of two or more with one or more organic diacids to form a reaction mixture, adding a first amount of dialkyl carbonate to the reaction mixture to remove water remaining from the reaction mixture by azeotropic drying, adding a transesterification catalyst to the dialkyl carbonate containing reaction mixture and adding a second amount of dialkyl carbonate to the catalyst containing reaction mixture. | 01-15-2015 |
20150025217 | YIELD OPTIMIZATION OF POLYCARBONATE POLYOLS - Embodiments of the invention provide for methods of producing a polycarbonate polyol. The method includes charging a vessel with butanediol, charging the vessel with a polymerization catalyst, and adding to the vessel dimethyl carbonate at a rate of at least 2.0 g of DMC per minute per kg of BDO to produce polycarbonate polyol at a polycarbonate polyol yield of at least 80% of a theoretical yield. | 01-22-2015 |
20150031815 | ESTER CARBONATE POLYOLS FOR HYDROLYTICALLY STABLE ADHESIVES - A two-component curable adhesive or sealant composition is provided. The first component may comprise a mixture of at least one polyol selected from the group comprising a polyester polyol, a polyester-polycarbonate copolymer polyol, and combinations thereof, a resin, and optionally a solvent. The second component may comprise a prepolymer obtained by reacting a polyester-polycarbonate copolymer polyol which is the reaction product of a polyester polyol which is the reaction product of one or more organic acids, and one or more glycols having a functionality of two or more and one or more polycarbonate polyols, at least one organic polyisocyanate component, and at least one chain extending agent and optionally a solvent. Alternatively, the first component may comprise a polyester-polycarbonate copolymer polyol, a resin, and optionally a solvent. The second component may comprise a polyisocyanate curative and optionally a solvent. The cured adhesive exhibits improved hydrolytic properties while maintaining excellent processability and adhesive properties. | 01-29-2015 |
20160069172 | ENHANCED STEAM EXTRACTION OF IN SITU BITUMEN - A process includes: (a) injecting a steam composition into a subterranean location containing bitumen, the steam composition containing an alkylene glycol ether and steam, wherein the alkylene glycol ether is other than a glycol ether amine; and (b) recovering bitumen from the subterranean location to above the ground. | 03-10-2016 |
Patent application number | Description | Published |
20130246118 | METHOD, APPARATUS, AND COMPUTER PROGRAM PRODUCT FOR A MARKET PLATFORM - Some examples provide systems, methods, apparatus, and computer program products for providing a market platform. The market platform may operate to inform buyers and suppliers, to allow buyers and suppliers to select products and contracting parameters to meet their needs, to allow buyers and suppliers to commit to supply agreements, and to enforce those supply agreements. These examples may provide such an integrated system by receiving buyer spend data, receiving contract offers from one or more suppliers based on the spend data, allowing the buyer to select one or more of the contract offers, and monitoring spend data to ensure compliance with the selected contract offer. The system may include dynamic pricing models, altering the price of the purchased products based on compliance with the selected contract offer. The system may also allow for various contracting models for managing the pricing of products based on the contractual terms agreed to by the buyer and supplier. | 09-19-2013 |
20130246221 | METHOD, APPARATUS, AND COMPUTER PROGRAM PRODUCT FOR CONTRACT COMPLIANCE MONITORING AND ENFORCEMENT - Some examples provide systems, methods, apparatus, and computer program products for monitoring and/or enforcing compliance with contract provisions. A market platform may operate to inform buyers and suppliers, to allow buyers and suppliers to select products and contracting parameters to meet their needs, to allow buyers and suppliers to commit to supply agreements, and to enforce those supply agreements. These examples may provide such an integrated system by receiving buyer spend data, receiving contract offers from one or more suppliers based on the spend data, allowing the buyer to select one or more of the contract offers, and monitoring spend data to ensure compliance with the selected contract offer. The system may include dynamic price models, altering the price of the purchased products based on compliance with the selected contract offer. The system may include provisions for monitoring achievement from buyer spend data, and monitoring and enforcing contract terms based on that achievement. | 09-19-2013 |
Patent application number | Description | Published |
20150125478 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING NEURONAL AND BRAIN TUMORS - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 05-07-2015 |
20150147347 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 95 novel peptide sequences and their variants derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses. | 05-28-2015 |
20160051654 | NOVEL IMMUNOGENIC EPITOPES FOR IMMUNOTHERAPY - The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. The present invention relates to novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumour cells which can be used in vaccine compositions for eliciting anti-tumour immune responses. | 02-25-2016 |